Wos İndeksli Açık & Kapalı Erişimli Yayınlar

Permanent URI for this communityhttps://hdl.handle.net/11727/10751

Browse

Filters

2018 - 20202

Settings

Author: search.filters.author.Firat, Alisearch.filters.applied.f.rights: search.filters.rights.info:eu-repo/semantics/openAccess

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Endovascular Treatment of Intracranial Aneursyms with Flow Diverter Stents
    (2020) Igus, Behlul; Selcuk, Hakan; Kara, Batuhan; Firat, Ali; Salik, Aysun Erbahceci; 0000-0003-4874-8141; AAN-1040-2021
    Objective: We aimed to present the treatment and follow-up results of 41 patients who were treated for intracranial aneurysm with flow diverter stents. Method: Forty-one patients (Age range 27-68 years) were treated with the flow- diverting devices during January 2010 and January 2014. Aneurysms ranged in size from small to large (1-30 mm) and include wide-necked aneurysms, multiple, saccular, blister, dissecan, fusiform and recurrent intracranial aneurysms. Control skull X-Ray Graphy was typically performed at 1, 3 and 6 months after treatment. A follow-up digital subtraction angiogram (DSA) was performed first day, 6 and 12 months after treatment. Conclusions: Complete angiographic occlusion was achieved in 36 patients (88%) at follow-up digital subtraction angiogram. Two transient morbidities and one permanent morbidity occurred due to stent thrombosis. There was no mortality observed. Flow diverter stents are an effective tool in the treatment of large wide neck, high growth rates, and technical problematic aneurysms to treat with conventional endovascular methods.
  • Thumbnail Image
    Item
    Evaluation of Prostatic Artery Embolization Efficiency in Benign Prostatic Hyperplasia Patients with High Comorbidity
    (2018) Duman, Enes; Yildirim, Ismail Okan; Firat, Ali; Celik, Huseyin; Sarac, Kaya
    Objective: The purpose of this study was to evaluate efficacy outcomes following prostate artery embolization (PAE) for the treatment of benign prostatic hyperplasia (BPH) patients with high comorbidity. Materials and Methods: This retrospective study included 22 patients treated with PAE from May 2015 to June 2017. Patients with Charlson comorbidity index >= 2, International Prostate Symptom Score (IPSS) >12, prostate specific antigen (PSA) levels <4 ng/mL or between 4 and 10 ng/mL with negative prostate biopsy and total prostate volume (TPV) >90 cm(3) were included. Total PSA, maximum flow rate (Q(max)), TPV, IPSS, post-voiding residual (PVR) values were recorded in all patients in the urology clinic before PAE and at 3 and 6 months after PAE. Results: The average patient age was 73.86 +/- 6.25 years and operative time was 80 minutes (range, 60-120 min). Pre-PAE and 6-month post-PAE values were: IPSS: 25.18 +/- 6.75 an d 11.27 +/- 3.29 (p<0.05), Q(max): 8.31 +/- 3.12 and 17.22 +/- 3.23 (p<0.05), PVR: 87.9 +/- 19.25 and 25.86 +/- 7.72 (p<0.05), TPV: 134.45 +/- 57.56 and 86 +/- 15.4 (p<0.05), and PSA: 3.89 +/- 1.26 and 2.11 +/- 1.06 (p<0.05). Embolization was performed unilaterally due to atherosclerosis and strictures in the internal iliac artery branches in 2 patients. After the procedure, 2 patients experienced transient hematuria which did not require bladder irrigation, 1 patient had acute urinary retention due to dysuria, and 1 patient had transient hematospermia. Conclusion: PAE may be an alternative treatment method in BPH patients with high comorbidity.